arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

aTYR PHARMA INC

ATYR
$0.52 ▲ +0.02 (+4.74%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
51 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

aTYR PHARMA INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $51.0M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -15.6%
FCF / Share $-0.13
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-10.79M
↑ +27.5%
Operating Margin Operating profit as % of sales
-76.5%
↑ +68.2%
FCF / Share Free cash flow per share
$-0.13
↑ +27.6%
Long-Term Debt Long-term obligations
$2.74M
↓ -40.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
8
Financial Health
5
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters